Survival in Norwegian BRCA1 mutation carriers with breast cancer
Tóm tắt
Several studies of survival in women with BRCA1 mutations have shown either reduced survival or no difference compared to controls. Programmes for early detection and treatment of inherited breast cancer, have failed to demonstrate a significant improvement in survival in BRCA1 mutation carriers. One hundred and sixty-seven women with disease-associated germline BRCA1 mutations and breast cancer from 1980 to 2001 were identified. Tumour characteristics, treatment given and survival were recorded. A control group comprising three hundred and four women matched for age, time of diagnosis and stage were used to compare survival.
BRCA1 mutation carriers were found to have a poorer prognosis, which could be explained by neither the mode of surgical treatment nor the use of adjuvant chemotherapy. BRCA1 mutation carriers with node negative breast cancer had worse overall survival than controls. Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when diagnosed at an early stage, and that type of treatment does not influence prognosis.
Tài liệu tham khảo
Johannsson OT, Idvall I, Anderson C, Borg Å, Barkardottir RB, Egilsson V, Olsson H: Tumour biological Features of BRCA1 -induced Breast and Ovarian Cancer. Eur J Cancer 1997, 33(3):362–71. 10.1016/S0959-8049(97)89007-7
Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK: Pathobiologic Characteristics of Hereditary Breast Cancer. Hum Pathol 1998, 29: 1140–4. 10.1016/S0046-8177(98)90427-0
Di Leo A, Cardoso F, Durbecq V, Giuliani R, Mano M, Atalay G, Larsimont D, Sotiriou C, Biganzoli L, Piccart MJ: Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol 2002, 7(4):245–53. 10.1007/s101470200036
Hagen AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO, Møller P, Lønning PE: Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. Acta Oncol 2007, 46(2):199–203. 10.1080/02841860600949552
Verhoog LC, Brekelmans CTM, Seynaeve C, Bosch LMC, Dahmen G, Van Geel AN, Tilanus-Linthorst MMA, Bartels CCM, Wagner A, Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn J: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 . Lancet 1998, 351: 316–21. 10.1016/S0140-6736(97)07065-7
Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressmann P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-Associated Breast Cancer in Young Women. J Clin Oncol 1998, 16(5):1642–9.
Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pyrhonen S, Blomqvist C, Pukkala E, Nevanlinna H, Sankila R: Survival of breast cancer patients in BRCA1 , BRCA2, and non- BRCA1 /2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 2001, 93(3):368–72. 10.1002/ijc.1341
Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, Steele L, Avizonis V, Stewart JR, Cannon-Albright LA: Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998, 47: 129–36. 10.1016/S0167-8140(98)00023-1
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, Weber BL: Effect of Radiotherapy after Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1 /2 Mutations. J Clin Oncol 2000, 18: 3360–9.
Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Brémond A, Treilleux I, Martin A, Romestaing P, Raudrant D, Rudigoz RC, Lenoir GM, Lasset C: Prognosis of early-onset breast cancer based on BRCA1 /2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 2007, 101: 233–245. 10.1007/s10549-006-9288-7
Foulkes WD, Wong N, Brunet J-S, Begin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN: Germ-Line BRCA1 Mutation Is an Adverse Prognostic Factor in Ashkenazi Jewish Women with Breast Cancer. Clin Cancer Res 1997, 3: 2465–9.
Foulkes WD, Wong N, Rozen F, Brunet J-S, Narod SA: Survival of patients with breast cancer and BRCA1 mutations. Lancet 1998, 351: 1359–60. 10.1016/S0140-6736(05)79091-7
Johannsson OT, Ranstam J, Borg Å, Olsson H: Survival of BRCA1 Breast and Ovarian Cancer Patients: A Population-Based Study From Southern Sweden. J Clin Oncol 1998, 16: 397–404.
Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D, Institut Curie Breast Cancer Group: Survival in early-onset BRCA1 breast-cancer patients. Lancet 1998, 352: 541. 10.1016/S0140-6736(05)79248-5
Foulkes WD, Chappuis PO, Wong N, Brunet J-S, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Begin LR: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000, 11: 307–13. 10.1023/A:1008340723974
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A, Institut Curie Breast Cancer Group, Asselain B: Familal Invasive Breast Cancers. Worse Outcome Related to BRCA1 Mutations. J Clin Oncol 2000, 18: 4053–9.
Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD: Germline BRCA1 /2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000, 18(24):4045–52.
Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet J-S, Hamel N, Paradis AJ, Boyd J, Foulkes WD: Impact of Germline BRCA1 Mutations and Overexpression of p53 on Prognosis and Response to treatment following Breast Carcinoma: 10-year follow up data. Cancer 2003, 97(3):527–536. 10.1002/cncr.11080
Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG: Survival and prognostic factors in BRCA1 -associated breast cancer. Ann Oncol 2006, 17(3):391–400. 10.1093/annonc/mdj095
Møller P, Borg Å, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, Mæhle L, Gregory H, Heimdal K: Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002, 101: 555–9. 10.1002/ijc.10641
Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P: Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007, 16: 367–74. 10.1016/j.breast.2007.01.006
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11: 359–77.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403–10. 10.1111/j.1365-2559.1991.tb00229.x
Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM: Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 2007, 121(5):1017–20. 10.1002/ijc.22789
Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Constanzo F, Boland CR, Venuta S: BRCA1 expression modulates chemosensitivity of BRCA1 -defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88(8):1285–91. 10.1038/sj.bjc.6600859
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007, 117(5):1370–80. 10.1172/JCI30866
Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA: Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations. New Engl J Med 2007, 357: 115–23. 10.1056/NEJMoa070608